Pancreatic Cancer Research

Clinical trialPhase 1Unknown

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

A Phase I Study to Assess the Tolerability, Safety and Efficacy of Fluzoparib in Combination With mFOLFIRINOX as Neoadjuvant and Adjuvant Therapy in Patients With Resectable Pancreatic Cancer

Outcome
Outcome unknown
Phase
Phase 1
Status
Unknown
Study type
Interventional
Start
17 December 2020
Listed end
1 September 2023
Enrollment
74 participants
Sites
1
Primary outcomes
Number of participants with a dose limited toxicity; Maximum tolerated dose; RP2D; R0 resection rate
Sponsor type
Industry
Results posted
No
Last update
31 December 2020

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The study is being conducted to: a) evaluate the tolerability and safety of the co-administration of Fluzoparib and FOLFIRINOX in patients with resectable pancreatic cancer, and establish a maximum tolerated dose and recommended phase II dose of the combination and b) assess the efficacy of the co-administration of Fluzoparib and FOLFIRINOX in patients with resectable pancreatic cancer.